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Abstract
Background: Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden
countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use
of rifampicin and several antiretroviral drugs is complicated by pharmacokinetic drug-drug interaction.
Method: Pubmed and Google search following the key words tuberculosis, HIV, emtricitabine, tenofovir efavirenz,
interaction were used to find relevant information on each drug of the fixed dose combination Atripla
R
Results: Information on generic name, trade name, pharmacokinetic parameter, metabolism and the
pharmacokinetic interaction with Anti-TB drugs of emtricitabine, tenofovir, and efavirenz was obtained.
Conclusion: Fixed dose combination of emtricitabine/tenofovir/efavirenz (ATRIPLA
R) which has been approved by
Food and Drug Administration shows promising results as far as safety and efficacy is concerned in TB/HIV co-
infection patients, hence can be considered effective and safe antiretroviral drug in TB/HIV management for adult
and children above 3 years of age.
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Background
Human immunodeficiency virus (HIV) and tuberculosis
(TB) are overlapping epidemics that cause an immense
burden of disease. Sub-Sahara Africa is a region most
affected by both diseases including Tanzania [1]. Litera-
tures show that more than 75% of TB patients have also
HIV, and possibly more than half of worldwide patients
infected with HIV will also develop TB [2,3]. Further-
more TB contributed to 27% of all AIDS diagnoses [4].
For TB the currently used combination drug regimens
produce cure rates that exceed 95%, given good patient
adherence during the multiple months’ treatment period
[5]. Also for HIV many regimens are available; however
optimal treatment regimens for TB/HIV co-infection are
not yet clearly defined.
As therapy for HIV disease becomes more available,
physicians need to know how to treat these two diseases
effectively while minimizing the risk of drug interactions
and maintaining the shortest possible duration of treat-
ment for TB. Current treatment of mycobacterium
tuberculosis in most resource limited settings is com-
prised of a four-drug initial anti-tuberculosis regimen
for 2 months (rifampicin, isoniazid, pyrazinamide and
ethambutol), followed by two-drugs continuation phase
of anti-tuberculosis regimen for 4 months (rifampicin
and isoniazid). For TB/HIV co-infected patients the
guidelines which exist [6] have shown many challenges.
Combining drug therapies for dual infection TB and
HIV is made complex by alterations in the activity of
the hepatic Cytochrome P450 (CYP) system, high pill
burdens, shared drug toxicities, drug-drug and drug-dis-
ease interactions, immune reconstitution inflammatory
syndrome, co-morbid diseases and drug resistance in
both bacillus and virus [7,8]. The CYP isoform enzymes
are responsible for many interactions [9] (especially
those involving rifampicin and isoniazid) during drug
biotransformation (metabolism) in the liver and/or
intestine, due to it is enzyme induction effect.
Presentation of the hypothesis
Adherence to a complex regimen is often a significant
barrier to treatment success. Following the current
g u i d e l i n ew h e r eap a t i e n th a st ot a k e4 - f i x e dd o s e
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therapy selected for HIV treatment. The consequence of
many pills reduce compliance and hence adherence to
the treatment regimen leading to suboptimal TB and
HIV treatment, hence increasing the possibility of drug
resistance and shared drug toxicities [10]. These toxici-
ties may necessitate therapy discontinuation, which
exacerbates immune suppression and predisposes to
other opportunistic infections.
TB/HIV co-infection simultaneous treatment have
shown pharmacokinetic interactions produced with
mainly rifampicin [(a cornerstone in TB treatment) and
the non nucleoside reverse transcriptase inhibitors
(NNRTIs)]. Enzyme inducer decreases elimination halve
life of nevirapine [11]. When rifampicin and nevirapine
are given together there is an observed 31% to 58%
decrease in plasma levels of nevirapine due to rifampicin
induction effect [12-15]. Available literatures explain
that rifampicin combination with efavirenz there is
reduction of serum levels of 13-33% [16], however no
virological failure reported to be significant [17]. HIV-
infected patients achieve somewhat lower concentrations
of the orally administered first-line anti-tubercular drugs
[18,19]. The effect of rifampicin on the concentrations
of Protease Inhibitors (PI) is well elaborated in a study
of Moreno et al. [20].
Immune reconstitution inflammatory syndrome (IRIS),
which is due to dysregulated immune recovery [21],
occurs in severely immune-suppressed HIV patients
normally 1 to 4 weeks after ART initiation [22,23]. In
tuberculosis-related IRIS which is an inflammatory reac-
tion is directed towards mycobacterial antigens [24],
resulting in worsening pulmonary infiltrates. Risk factors
for TB-IRIS include low baseline CD4 count, high base-
line viral load, short duration between TB and ART
initiation and disseminated tuberculosis [22,25], making
difficult to determine the optimal time to initiate ART
in severely immune-suppressed TB patients [26,27].
Immune reconstitution is based on the patient’s ability
to respond to treatment. For the most part, in patients
with CD4 counts of 200-350 cells/mm
3 who start treat-
ment, their immune systems still have the ability to be
activated to produce more CD4 cells [28]. In contrast,
in patients with low CD4 counts (< 100 cells/mm
3), it
m a yb em o r ed i f f i c u l tt oa c t i v a t et h e i ri m m u n es y s t e m s
to produce many CD4 cells because of existing damage
from the virus.
In the management of TB/HIV co-infection directly
observed therapy and other adherence promoting strate-
gies should be used in all patients with HIV-related TB
[29]. Whenever possible, the care for HIV-related TB
should be provided by or in consultation with experts in
management of both TB and HIV. The care for persons
with HIV-related TB should include close attention to
the possibility of TB treatment failure, antiretroviral
treatment failure, paradoxical reactions, side effects for
all drugs used, and drug toxicities associated with
increased serum concentrations of rifampicin.
Due to these accompanied complications, selecting an
appropriate antiretroviral therapeutic regimen is war-
ranted. This involves addressing multiple interdependent
issues, including patient adherence, pharmacokinetic
properties of the drugs (including food effects and drug-
drug interactions), drug resistance, and overlapping
adverse effects. On 12 July 2006 Bristol-Myers Squibb
and Gilead Sciences announced that the US Food and
Drug Administration (FDA) had cleared Atripla
R,t h e i r
fixed-dose combination tablet. Atripla
R is a complete
regimen in a single, fixed-dose combination tablet that
contains: efavirenz 600 mg, emtricitabine 200 mg and
tenofovir disoproxil fumarate 300 mg. It is a novel co
formulation drugs from two different classes, simplifying
administration and increasing adherence too [30].
Testing the hypothesis
A new formulation combining fixed doses of the
nucleoside reverse transcriptase inhibitors emtricita-
bine (200 mg) and tenofovir disoproxil fumarate (teno-
fovir DF; 300 mg) with the non-nucleoside reverse
transcriptase inhibitor efavirenz (600 mg) represents
the first once-daily, one-tablet antiretroviral regimen.
Co-formulated efavirenz/emtricitabine/tenofovir DF
demonstrated excellent potency, tolerability and favor-
able safety profile [31].
Co administration of co-formulated efavirenz/emtrici-
tabine/tenofovir DF with rifampicin based TB regimen
clinical trials is going on in TB/HIV patients of Tanza-
nia, therefore is important to have knowledge of each
individual drug. Also a once-daily regimen of efavirenz,
emtricitabine and tenofovir DF (administered as indivi-
dual agents) was superior to once-daily efavirenz plus
twice-daily co-formulated lamivudine/zidovudine in
terms of virological suppression, immunological recov-
ery and adverse events [32]. Individually, these agents
have long half-life that allow for once-daily dosing.
Emtricitabine emtriva
R a cytosine analogue is the
newest of the nucleoside reverse transcriptase inhibitor
(NRTI) drugs. It was well tolerated in clinical trials
where most adverse events were consistent with the
NRTI class. Moreover, emtricitabine based regimens
were as well tolerated as those with lamivudine [33].
Emtricitabine has no currently known phase I (glucuro-
nidation) or phase II (cytochrome P450 and others)
interactions [34]. It may be taken with or without food
[35]. Emtricitabine displays dose-proportional pharma-
cokinetics. Bioavailability is not affected by food intake.
Mean steady-state Cmax,T max and AUC values were 1.7
mg/L, 2 h, and 10 mg/L.h respectively in 6 patients with
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the intracellular half-life of the active compound, emtri-
citabine-triphosphate is mu c hl o n g e r :3 9hw h i c hs u p -
port the once daily dosing.
Tenofovir disoproxil fumarate Viread
R is an analo-
gue of adenosine five monophosphate. It is a nucleotide
analogue and consequently its mechanism of action dif-
fers from that of nucleoside analogues. It is a prodrug,
therefore after absorption the drug is hydrolyzed and
the active compound tenofovir-diphosphate is released.
It has a longer serum half-life than most other NRTIs
allowing a once daily dosing. The plasma half-life is 14.4
h, but the intracellular elimination half-life of the active
compound, tenofovir-diphosphate is much longer > 49
h.
This drug has broad tissue distribution, aided by its
small molecular size and very low protein binding, and
is eliminated as unchanged drug in the urine through
glomerular filtration and active tubular secretion.
Because of this latter characteristic, dosage adjustments
are required in patients with renal insufficiency [36]. 70-
80% of a dose is recovered unchanged in the urine, sug-
gesting minimal influence of hepatic metabolism. Teno-
fovir mean steady-state Cmax,T max and AUC were 0.33
mg/L, 2.3 h, and 3.0 mg/L.h respectively in patients
infected with HIV. Adverse reactions are relatively
uncommon, and nausea is the most often reported
symptom [37]. The bioavailability of tenofovir disoproxil
fumarate is increased in the presence of a high fat diet
(40%-50%), and the drug should be taken with food,
[38,39]
Tenofovir disoproxil fumarate is not a substrate, inhi-
bitor, or inducer of the P450 system, within the class of
antiretroviral agents, an increase in the bioavailability of
didanosine has been described, leading to the recom-
mendation that the dose of didanosine be reduced when
used in combination with tenofovir. Tenofovir can be
used without adjustments with other nucleoside and
nonnucleoside reverse transcriptase inhibitors. Equally,
tenofovir seems to have no effect on the pharmacoki-
netics of protease inhibitors although these latter agents
may produce a slight increase in the bioavailability of
tenofovir, which seems to be of little clinical relevance.
Efavirenz Sustiva
R is a NNRTI which is principally
metabolized by cytochrome P450, more precisely isoen-
zymes CYP2B6 and CYP3A4. No active metabolites are
formed. Efavirenz has a long terminal half-life of 40-55
h after multiple dosing. Neuropsychiatric symptoms are
the common side effects observed. Fumaz et al. [40], in
a randomized, prospective, two-arm controlled study
compared quality of life and neuropsychiatric side
effects in patients receiving an efavirenz-containing regi-
men versus a group whose treatment did not include
efavirenz. They found that the group receiving an
efavirenz-containing regimen reported a better quality of
life, particularly because their regimen was easier. They
found, however, that 13% of their patients reported
“character change”. Meals of normal composition have
no appreciable effect on the pharmacokinetics of efavir-
enz. The bioavailability is increased following a high fat
meal. Time to peak plasma concentration is 3-5 h.
Steady state concentrations are achieved after 6-7 days.
Mean steady state Cmax,C min and AUC(0-24 h) were 4.1
mg/L, 1.8 mg/L and 58.1 h*mg/L respectively after mul-
tiple dosing of 600 mg efavirenz once daily.
Several pharmacokinetic studies have been conducted
showing the interaction of rifampicin with efavirenz.
Lopez-Cortez et al. [16] in Spain did on 24 patients with
concomitant infections of HIV and tuberculosis. It was
nonblinded study where group A (n = 16) received anti-
tuberculosis drugs without rifampicin but with added
efavirenz 600 mg/day ARV regimen. The patients were
then switched to a standard antituberculosis regimen
containing rifampicin with efavirenz 600 mg/day (group
A1; n = 8) or efavirenz 800 mg/day (group A2; n =8 ) .
The result showed that levels of AUC, Cmax, and Cmin
of efavirenz decreased respectively by 24%, 25%, and
22%, after addition of rifampicin to the efavirenz of 600
mg/day group. Significant association of body weight,
dose of efavirenz and its pharmacokinetic parameters
w a so b s e r v e da n dt h ed o s ei n c r e a s et o8 0 0m g / d a y
when efavirenz is used with rifampicin was
recommended.
Manosuthi et al. [17,41] conducted a non-blinded ran-
domized clinical trial to Thai patients and they were
given rifampicin for more than 1 month with regimen
containing efavirenz 600 mg/day (n = 42), or efavirenz
800 mg/day (n = 42). The plasma concentrations of efa-
virenz were determined for both groups 12 h after drug
administration and on day 14. Both groups had 12-h
efavirenz concentrations (C12) of same value (median
3.0 mg/L vs 3.3 mg/L); but the upper C12 levels were
higher in the group receiving efavirenz at the dosage of
800 mg/day (21.3 mg/L) in comparison with the group
on 600 mg/day (12.2 mg/L). The study concluded that
efavirenz with a dose of 600 mg/day is adequate for the
majority of HIV-infected patients in Thailand (as their
body weight is around 50 kg) but more studied should
b ep e r f o r m e dt oo t h e re t h n i cg r o u p s .T h i si si nl i n e
with a recent study by Orrell [42] which showed that
600 mg dose of efavirenz is adequate.
Another study was conducted aiming at determining
the effects of higher body weights and differing ethnici-
ties on exposure to efavirenz. 9 patients with body
w e i g h t so fo v e r5 0k gw e r ee nrolled in the study [43].
The patients received an antiretroviral regimen contain-
ing efavirenz 800 mg/day and antituberculosis therapy
containing rifampicin. Plasma concentrations of
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sub-therapeutic trough concentrations of efavirenz
(median 11.7 mg/L; range 5.37-19.6 mg/L). The
expected therapeutic range of trough concentrations of
efavirenz were between 1.2 and 4.0 mg/L. Seven out of
the 9 patients with HIV/TB co-infection had toxicity (6
of them black and 1 caucasian). Around 20% of ethnic
Black Africans possess homologous G516T alleles versus
3% of Caucasians [44]. This CYP2B6 polymorphism is
associated with exposure to higher concentrations of
efavirenz.
Existence of a wide variability in efavirenz concentra-
tions among black Africans was observed in the study of
Friedland et al. [45]. This study indicated that inter-sub-
ject variability in efavirenz concentrations was greater
when the drug was administered with rifampicin (coeffi-
cient of variation [CV] 157%) compared with the inter-
subject variability after discontinuation of rifampicin
(58%), with much of consistent intra-subject variation
over time (CV 24%). However, Cmin was not signifi-
cantly different during versus post TB therapy.
Regarding metabolism studies have shown that
CYP2B6 genetic polymorphisms influence very much
efavirenz elimination [46-48]. CYP2B6 polymorphisms
have been associated with altered PK of efavirenz in
HIV-infected adults and children [49-51] resulting in a
higher efavirenz exposure and an increase in central
nervous system side effect [44,46]. CYP2B6 patients are
poor metabolizer of the drug and dose reduction has
been proposed to people with this genotype [52,53]. Of
note: is the high prevalence of efavirenz related CYP2B6
polymorphisms in patients of African region which
represent the majority of the HIV-infected population in
the world [54-58]. This indicates the need for prospec-
tive clinical studies to evaluate the utility of dose adjust-
ments in these populations.
Use of efavirenz in children
The use of efavirenz as a component of first-line antire-
troviral therapy in adult and children above 3 years has
been accepted worldwide [59], however safety and effi-
cacy of efavirenz in children less than 3 years of age has
not been performed [60-63] and the data on the efavir-
enz exposure in mothers and their breastfed infants is
also limited [64]
Despite the report that efavirenz is highly effective and
well tolerated in the majority of pediatric patients [65],
efavirenz plasma concentrations have been reported to
be suboptimal in a large proportion of children and ado-
lescents dosed according to current pediatric guidelines
[60,61] Also interindividual variability has been observed
in paediatric population [66].
Recently data on population pharmacokinetics (PK) of
efavirenz in children predicts sub-therapeutic efavirenz
exposure in a significant proportion on children with
the currently recommended efavirenz dose [61,67].
Authors in ARROW study which was done recently in
Uganda and Zimbabwe [68] suggested the use of higher
paediatric efavirenz doses, as per WHO 2010 recom-
mendations, however they concluded that children with
toxic level of efavirenz concentration may be increased.
Also efavirenz pharmacokinetics was shown to demon-
strate significant age effects with apparent clearance
much greater in young infants than older children. High
efavirenz dose requirements and pharmacokinetic varia-
bility in infants will require additional pharmacokinetic
studies to determine appropriate efavirenz dosing strate-
gies. Therefore priorities should be made to access the
developmental changes of efavirenz exposure in children
and adolescents and application of therapeutic drug
monitoring to the settings where the facility is available.
Implication of the hypothesis
HAART regimens have contained very high pill burdens,
complex dosing schedules, and specific food require-
ments. The management of HIV-related tuberculosis
disease seems to be complex although the treatment of
TB in persons with HIV is essentially the same as for
patients without HIV. A major concern in treating TB
in HIV-infected persons is the interaction of rifampin
with certain antiretroviral agents, PIs and NNRTIs
[69,70]. Rifabutin, which has fewer drug interactions,
may be used as an alternative to rifampicin but is
expensive and not available in resource limited area.
Pharmacokinetic data which are present indicate that
rifampicin can be combined with efavirenz [16,17].or
nevirapine,[14] although for TB/HIV co-infected
patients who got 600 mg rifampicin, adverse events
were reported to be higher in nevirapine based regimen
compared to efavirenz based regimen [71]. Non-boosted
PIs cannot be administered with rifampicin because of
considerable decreases in plasma concentrations of PIs,
which may cause sub-therapeutic concentrations except
ritonavir[72,73]. Ritonavir is a strong inhibitor of
CYP3A4 and P-glycoprotein, and when it is low dose is
combined with other PIs an important increase in their
plasma concentrations is achieved, however this is not a
solution as substantial decreases in plasma concentra-
tions of indinavir,[74] lopinavir [75] and atazanavir [76]
have been observed when co-administered with rifampi-
cin, even when small doses of ritonavir are given.
Another promising PI is saquinavir although in a study
of Ribera et al. [77] a decrease of 40%, 35% and 49% in
the median saquinavir AUC0-24,C m a xa n dC t r o u g h ,
respectively, were observed.
In vitro study reveals the benefit from the use of com-
bination therapy achieved with Atripla in terms of the
emtricitabine and tenofovir intracellular drug
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HIV positive only hence more data are needed from
TB/HIV co-infected patient.
HIV fusion inhibitors represent a novel class of antire-
troviral drugs and enfuvirtide is the first drug within
this class to be approved [79]. When combined with
active ARV drugs, different studies reported findings of
substantial improvements in virological, immunological
and clinical outcomes [80-83]. It has little potential for
drug-drug interactions as far as coadministration with
T Bd r u g si sc o n c e r n e d[ 7 9 , 8 4 , 85]. The major limitation
of this drug is the twice daily dosing which may inter-
fere with the treatment adherence. Injection-site reac-
tions occurred almost universally in its recipients,
although did not necessitate stopping treatment.
Co-formulated atripla
R (emtricitabine/tenofovir/efavir-
enz) have demonstrated excellent potency, tolerability
and favorable safety profile. The drug is now available in
most of the limited-resources countries. The drug is
given once per day simplifying administration and
increasing adherence too, hence may be recommended
as a way to jointly treat these two diseases.
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